Aldeyra Therapeutics, Inc.

Healthcare · Biotechnology

1.20$ -1.2% vs. previous close Closing price · As of: Sep 25, 2026

Statements

Balance Sheet

Aldeyra Therapeutics, Inc. (ALDX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 48 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size %

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet ALDX
Line item	Q3 16	Q4 16	Q1 17	Q2 17	Q3 17	Q4 17	Q1 18	Q2 18	Q3 18	Q4 18	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Total Assets	29	25	32	26	49	44	41	43	37	95	88	74	77	76	63	72	88	83	147	256	247	233	223	201	190	181	168	156	147	148	141	126	117	105	93	85	78	72	66	48
Current Assets	29	25	31	26	49	44	41	43	37	95	87	73	77	75	63	71	88	83	147	256	247	233	222	201	189	181	168	155	147	148	141	126	117	104	93	85	77	72	66	47
Cash	15	12	19	15	33	20	21	25	18	47	44	39	52	44	39	61	86	78	138	250	241	230	159	121	129	144	165	152	143	143	102	71	68	55	50	41	59	70	65	45
Cash & Short-Term Investments	29	25	31	26	48	43	39	42	35	94	82	69	76	73	61	66	86	78	138	250	241	230	217	197	185	174	165	152	143	143	133	120	113	101	90	82	75	70	65	45
Receivables	–	–	–	–	–	18	–	17	11	44	39	32	26	28	23	10	15	25	50	125	125	0.0	65	79	22	3.2	0.0	–	–	–	50	40	40	–	0.8	–	–	–	–	–
Inventory	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	–	–	–	–	–	–	–	–	–	-42	-120	-120	-123	-60	-75	-22	-3.2	0.0	–	–	–	–	–	–	–	–	–	–	–	–	–
Property, Plant & Equipment	0.1	0.1	0.1	0.0	0.0	0.0	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.4	0.0	0.0	0.0	0.2	0.0	0.0	0.1	–	–	–	–	–	–	–	–	–	–	–	–
Goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Intangible Assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Total Liabilities	3.5	3.5	3.5	3.1	3.3	4.6	4.8	6.3	8.5	8.5	9.6	6.5	27	27	20	19	19	24	21	23	28	27	32	27	27	30	31	26	24	29	28	28	32	34	30	30	29	28	24	9.7
Current Liabilities	2.6	2.3	2.4	2.1	2.4	3.4	3.7	5.3	7.7	8.5	9.5	6.4	12	13	4.9	4.9	6.5	12	11	7.4	12	12	16	16	24	15	16	16	22	22	22	28	17	19	14	30	28	28	24	9.7
Short-Term Debt	0.4	0.1	0.2	0.3	0.4	0.1	0.2	0.3	0.5	–	0.2	0.2	0.2	0.2	0.2	1.0	2.3	3.9	5.3	0.1	0.2	0.2	0.2	5.2	13	1.2	1.1	6.0	14	15	15	15	0.5	0.3	0.3	15	15	16	16	0.1
Accounts Payable	0.7	0.3	0.7	0.8	0.5	1.0	1.6	0.8	3.4	3.1	4.0	2.8	0.6	0.8	1.1	0.2	0.1	0.4	0.4	1.1	0.5	1.0	2.4	0.3	1.3	0.1	0.4	0.3	0.2	1.3	0.3	0.3	0.2	0.2	0.3	1.5	0.0	0.2	0.1	0.1
Long-Term Debt	0.9	1.2	1.1	1.0	0.9	1.2	1.1	1.0	0.9	–	0.2	–	14	15	15	14	13	11	10	15	15	16	16	11	3.3	15	15	10	2.7	–	–	–	15	15	15	–	–	–	–	–
Shareholders' Equity	26	22	28	23	46	40	36	37	29	87	78	67	51	48	43	53	69	60	126	234	220	206	191	174	162	151	137	130	123	120	113	98	85	71	64	55	49	44	42	38
Retained Earnings	-73	-77	-82	-88	-93	-100	-108	-117	-128	-139	-154	-167	-186	-199	-209	-217	-226	-237	-248	-263	-279	-295	-311	-329	-344	-357	-372	-381	-390	-394	-402	-419	-434	-450	-460	-470	-477	-484	-487	-493
Shares Outstanding	12	14	14	15	16	19	19	20	21	27	27	27	27	29	29	30	38	39	46	54	58	58	58	58	58	59	59	59	59	59	59	59	60	59	60	60	60	60	60	60

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Balance Sheet

Cookie settings